The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...

Keratoacanthoma (KA) is an epidermal tumor believed to arise from hair follicles and pilosebaceous units. There is an ongoing controversy as to whether KA should be classified as a benign or a ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Please provide your email address to receive an email when new articles are posted on . The subcutaneous pembrolizumab combination was approved for adults and ...

The following text summarizes information provided in the video. Elliptical excision of the skin is an essential procedure that can be used in the diagnosis and management of skin lesions and ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Background A 60-year-old female with a 6-month history of muscle-invasive transitional cell carcinoma of the bladder presented with an enlarging subcutaneous lesion involving her right flank. She had ...

Symmetrical—lesions appear to be distributed in a similar arrangement on differing sides of the body (Figure 3, see slideshow) Once the configuration and distribution has been determined, the next ...

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of ...

A 21-month-old male Swiss OF1 mouse from the breeding colony of the Experimental Animal Service of the University of Córdoba was presented to the veterinarian. The mouse had a raised, ulcerated mass ...

For over eight years, a 37-year-old, Delhi-based woman silently battled a painful, discharging lesion on her lower back. The condition, located in the sacrococcygeal region near her tailbone, was ...

Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to ...